Joseph W Kim, MD

Assistant Professor of Medicine (Medical Oncology)

Physician Biography

During his time at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors, for prostate cancer and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). His research interests are in early drug development, particularly immunotherapies for genitourinary cancers and others, as well as in development of biomarkers to predict responses to immunotherapy and those to identify aggressive prostate cancers at high risk of recurrence and progression. He is an active member of Society of Immunotherapy of Cancer and ASCO. His clinical interest is in care of patients with prostate cancer at various stages, muscle invasive bladder cancer and those with metastatic disease.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Early Drug Development Program | Subset Medical Oncology Faculty

Cancer Center, Yale: Prostate and Urologic Cancers Program

Medical Oncology

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine)

  • Internal Medicine AB of Internal Medicine (2010)

  • Medical Oncology AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Unknown Sites, Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary M14-546 - Phase I Dose Escalation of ABBV-075
Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Soft Tissue, Phase I Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer
Prostate A Phase I/II Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in mCRPC
Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites A Phase 1B Dose-Escalation Study of GDC-0919 With MPDL3280A in Patients with Advanced or Solid Tumor
Anus, Bladder, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mycosis Fungoides, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I Exploring the safety, tolerability, effect on tumor environment and efficacy of INCB combinations
Prostate VT-464 in Patients W/Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Anus, Bladder, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Anus, Bladder, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Phase I A Dose-Escalation Study of MOXR0916 & MPDL3280A in Locally Advanced or Metastatic Solid Tumors
Breast - Female, Colon, Hodgkin's Lymphoma, Lung, Non-Hodgkin's Lymphoma, Ovary, Pancreas NCI 7977
Bladder WO29636: IMvigor 010 Study: Anti-(PD-L1) Antibody MPDL3280A Treatment vs. Versus Observation
Bladder S1314 (COXEN) with neoadjuvant therapy for localized, muscle invasive bladder cancer
Prostate, Phase I EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Prostate ARMOR3-SV: Phase 3 trial of Galeterone Compared to Enzalutamide AR-V7 M1 CRPC
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Leukemia, not otherwise specified, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic Patient-Derived Models Tissue Procurement Protocol for NCI
Anus, Bladder, Breast - Female, Breast - Male, Colon, Esophagus, Hodgkin's Lymphoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites Phase 1-2 Study of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Cervix Uteri, Ovary, Phase I D3610C00001 - Phase I of AZD5363 under Adaptable Dosing Schedules in Solid Tumors
Bladder, Breast - Female, Colon, Lung, Ovary, Phase I PHASE IB STUDY WITH EXPANSION PHASE TO EVALUATE RO5509554 AND MPDL3280A

Edit this profile

Contact Info

Joseph W Kim, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste north Pavilion 8 & 4

New Haven, CT 06510
View on map...
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028